<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autosomal dominant polycystic kidney disease (ADPKD) in adults: Epidemiology, clinical presentation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vicente E Torres, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William M Bennett, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald D Perrone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder, occurring in approximately 1 in 1000 live births [<a href="#rid1">1-3</a>]. It is estimated that less than one-half of these cases will be diagnosed during the patient's lifetime, as the disease is often clinically silent [<a href="#rid1">1</a>].</p><p>Approximately 78 percent of families with ADPKD have an abnormality on chromosome 16 (<em>PKD1</em> locus) [<a href="#rid4">4</a>]. Most of the remaining families (14 percent) have a different defect that involves a gene on chromosome 4 (the <em>PKD2</em> locus), while a minority of families have a defect in the <em>GANAB </em>gene, encoding the glucosidase II alpha subunit, the <em>ALG9 </em>gene<em> </em>or the <em>DNAJB11 </em>gene [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/1682.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Genetics of the disease and mechanisms of cyst growth"</a>.)</p><p>Patients with <em>PKD2</em> have a less severe phenotype than those with <em>PKD1</em>, but neither disorder is benign [<a href="#rid6">6</a>]. Cysts occur later in <em>PKD2</em> disease, as does end-stage kidney disease (ESKD; mean age 74.0 versus 54.3 years in <em>PKD1</em>) [<a href="#rid7">7</a>]. </p><p>The epidemiology, clinical presentation, and diagnosis of ADPKD in adults will be reviewed here. The treatment of adults with this disease is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Treatment"</a>.) </p><p>The clinical presentation, diagnosis, and management of ADPKD in children is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15319.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD) in children"</a>.)</p><p class="headingAnchor" id="H1433315213"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>ADPKD occurs in all races and has a reported prevalence of 1:1000 [<a href="#rid8">8</a>]. ADPKD is the underlying cause of kidney disease in approximately 5 percent of patients who initiate dialysis annually in the United States [<a href="#rid9">9,10</a>].</p><p>ADPKD is predominantly caused by mutations in one of two genes: <em>PKD1</em> (which encodes polycystin-1) on chromosome 16 and <em>PKD2</em> (which encodes polycystin-2) on chromosome 4 [<a href="#rid9">9</a>]. Among most patients, kidney function remains intact until the fourth decade of life. Once the glomerular filtration rate (GFR) starts to decline, the average reduction is 4.4 to 5.9 mL/min per year [<a href="#rid8">8</a>].</p><p>Risk factors that have been identified for progressive kidney disease in ADPKD include [<a href="#rid6">6,11-23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic factors</strong> – The causative gene mutation is the major factor that determines the rate of progression among individual patients [<a href="#rid24">24</a>]. Patients with <em>PKD2</em> develop fewer cysts and progress more slowly than those with <em>PKD1</em> [<a href="#rid24">24,25</a>]. The median age of the onset of end-stage kidney disease (ESKD) was 54 and 74 years for <em>PKD1</em> and <em>PKD2</em>, respectively, in two studies [<a href="#rid7">7,25</a>]. </p><p></p><p class="bulletIndent1">Less than 2 percent of patients have deletions involving both th<em>e PKD1</em> gene and the tuberous sclerosis complex-2 gene, resulting in a more severe cystic kidney disease called the contiguous gene syndrome [<a href="#rid24">24</a>]. Truncating mutations in<em> PKD1</em> produce more severe disease than missense mutations [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1">Among patients with known PKD and a family history of PKD of unknown genotype, the careful attention to family history may allow the prediction of the mutation. This was shown in a study of 484 patients from 90 families with well-characterized ADPKD mutations. To predict <em>PKD1</em> or <em>2</em>, various age cutoffs for the onset of ESKD or for kidney survival without ESKD of affected family members were analyzed [<a href="#rid27">27</a>]. The following observations were made:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of at least one family member who developed ESKD before age 55 years predicted a <em>PKD1 </em>mutation with a positive predictive value of 100 percent and a sensitivity of 72 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of at least one family member who reached 70 years of age without ESKD predicted a <em>PKD2 </em>mutation with a positive predictive value of 100 percent and a sensitivity of 74 percent.</p><p></p><p class="bulletIndent1">Since neither criterion had a negative predictive value of 100 percent, the absence of an affected family member who satisfied these criteria did not allow for exclusion of either mutation.</p><p></p><p class="bulletIndent1">In addition, extensive variability in disease severity is common within families. Intrafamilial variability may be explained by somatic mosaicism, in which th<em>e PKD1</em> mutation is not expressed in all cells [<a href="#rid28">28,29</a>], or by modifier genes that are inherited independently of the PKD mutation [<a href="#rid9">9,11,30-32</a>]. Candidate modifier genes include the angiotensin I converting enzyme gene [<a href="#rid33">33</a>], the cystic fibrosis transmembrane conductance regulator gene [<a href="#rid34">34,35</a>], the endothelial nitric oxide synthase gene [<a href="#rid8">8</a>], and the Dickkopf 3<em> </em>(<em>DKK3</em>) gene. </p><p></p><p class="bulletIndent1">The patients with <em>GANAB</em> or <em>ALG9</em> mutations usually have mild PKD that rarely progresses to ESKD and variable polycystic liver disease [<a href="#rid5">5,36</a>]. </p><p></p><p class="bulletIndent1">The patients with <em>DNAJB11</em> mutations have small bilateral kidney cysts without marked kidney enlargement and generally develop ESKD at an advanced age (60 to 90 years) [<a href="#rid37">37,38</a>]. Concomitant polycystic liver disease is rare [<a href="#rid38">38</a>]. <em>DNAJB11</em> has features similar to autosomal dominant tubulointerstitial disease caused by <em>UMOD</em> or <em>MUC1 </em>mutations [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1">Mild PKD can also be observed with mutations more commonly associated with autosomal dominant polycystic liver disease (PRKCSH, SEC63, LRP5, ALG8, and SEC61B) [<a href="#rid39">39,40</a>]. In approximately 8 percent of families with mild ADPKD, no mutation is detected [<a href="#rid4">4</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney size </strong>– The rate of kidney growth is quasi-exponential, unique to and variable among patients, and kidney growth precedes decline in GFR [<a href="#rid17">17-19</a>]. Height-adjusted total kidney volume (htTKV) in concert with age predicts future GFR decline. </p><p></p><p class="bulletIndent1">The Mayo imaging classification is a simple tool that uses htTKV and age to identify patients at the highest risk for progression independent of kidney function [<a href="#rid22">22,23</a>]. Most patients with ADPKD (approximately 95 percent) have typical disease with diffuse cystic involvement (class 1). Patients with class 1 are further stratified into five subclasses (A to E) on the basis of growth rates (&lt;1.5, 1.5 to &lt;3, 3 to &lt;4.5, 4.5 to &lt;6, or ≥6 percent per year) estimated from patient age and a theoretical starting htTKV (150 mL/m)  (<a class="graphic graphic_figure graphicRef121627" href="/z/d/graphic/121627.html" rel="external">figure 1</a>) [<a href="#rid41">41,42</a>]. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mayo.edu%2Fresearch%2Fdocuments%2Fpkd-center-adpkd-classification%2Fdoc-20094754%29.&amp;token=lf7WBrokVl9y0kVR4Ruv7jTHxNo57Hs7oiHCVdTfG3QW0nbNii7nu%2FUkv0l5dnnvF9MaRQWN7xJBixhWX9gbHypVm%2FDjUYzjokLqBdQJNUyzvMstXQ0KMm9WkkjCP%2Fan&amp;TOPIC_ID=1678" target="_blank">A model</a> that uses this classification plus estimated GFR (eGFR) predicts future eGFR decline with reasonable accuracy. </p><p></p><p class="bulletIndent1">In the approximately 5 percent of patients displaying atypical kidney imaging (class 2), htTKV does not predict eGFR decline. Most patients with htTKV class 2 have focal cystic disease, and a few are older individuals with atrophic kidneys with cysts. The Mayo imaging classification has been validated by an independent study [<a href="#rid43">43</a>] and shown to be informative in post-hoc analyses of several clinical trials [<a href="#rid44">44,45</a>]. It is now often used to identify patients with rapidly progressive disease who are most likely to be informative in clinical trials and to benefit from proven effective therapies as they become available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension </strong>– Patients with larger kidneys tend to develop hypertension earlier in life, even before a decline in GFR, and this is a risk factor for progressive disease [<a href="#rid15">15,19,46</a>]. Issues related to hypertension in ADPKD, including the goal blood pressure, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1675.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Evaluation and management of hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early onset of symptoms </strong>– Patients who present with symptoms at an early age are more likely to develop ESKD [<a href="#rid13">13,14,23</a>]. In one study, patients diagnosed before the age of 30 years had a mean kidney survival that was 10 years less than those diagnosed after the age of 30 years [<a href="#rid13">13</a>]. There has been a trend for earlier diagnosis of ADPKD in patients at risk for the disease. In one cohort of patients, for example, the age at diagnosis was significantly lower among those born between 1951 and 1974 compared with those born before 1951 (27 versus 39 years, respectively) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Male sex </strong>– Male sex is associated with more rapid progression of <em>PKD1</em> in most [<a href="#rid12">12,15,48</a>], but not all [<a href="#rid49">49</a>], studies. The reasons for this are not known [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proteinuria </strong>– Patients who have dipstick-positive proteinuria and moderately increased albuminuria (formerly called "microalbuminuria") account for approximately one-fourth of those with ADPKD. Such patients are at greater risk for progression to ESKD. Proteinuria also associates with kidney size, hypertension, and reduced kidney function [<a href="#rid15">15,51-53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High urinary sodium excretion </strong>– Higher urinary sodium excretion is associated with a more rapid decline in eGFR [<a href="#rid20">20</a>]. The underlying mechanism is unknown.</p><p></p><p class="headingAnchor" id="H938638836"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Virtually all individuals who inherit <em>PKD1</em> or <em>PKD2</em> mutations eventually develop kidney cysts that are visible by ultrasonographic imaging studies [<a href="#rid54">54</a>]. The age at which affected individuals have clinical manifestations, such as kidney function impairment or hypertension, is variable. As discussed above, patients with <em>PKD1</em> present with symptoms at a younger age than those with <em>PKD2 </em>mutations. At any given age, patients with <em>PKD1</em> typically have larger kidneys and more cysts than those with <em>PKD2</em> [<a href="#rid55">55</a>]. In one study, the median age of patients who presented with end-stage kidney disease (ESKD) was 54 and 74 years for those with <em>PKD1</em> and <em>PKD2</em>, respectively [<a href="#rid7">7</a>]. However, early-onset disease has been described with both mutations [<a href="#rid26">26,56</a>]. </p><p>Patients with ADPKD can present with hypertension, hematuria, proteinuria, or kidney function impairment. Flank pain, due to kidney hemorrhage, obstructive calculi, or urinary tract infection, is the most common symptom reported by patients [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/1680.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Kidney manifestations"</a>.)</p><p>Hypertension is present in the majority of patients who have normal kidney function and have reached the fourth decade of life; the prevalence of hypertension increases to almost 100 percent among patients with ESKD [<a href="#rid9">9</a>]. </p><p>Patients may also present with symptoms that are secondary to cysts in other organs, such as the liver, pancreas, spleen, or epididymis. (See  <a class="medical medical_review" href="/z/d/html/1679.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Extrarenal manifestations"</a>.)</p><p>Large kidney and hepatic cysts can compress the inferior vena cava (IVC) and, when the obstruction is severe, lead to hypotension, thromboembolism, and hepatic venous outflow obstruction [<a href="#rid57">57-63</a>]. In one study, approximately one-third of patients with ADPKD had ≥50 percent compression of their IVC compared with age- and sex-matched controls [<a href="#rid64">64</a>]. However, among patients who had IVC compression, complications were uncommon and typically occurred in the presence of additional risk factors (eg, pregnancy, hypercoagulability).</p><p>The diagnosis is most commonly made in the settings of routine evaluation in an asymptomatic patient with a positive family history of ADPKD, initial work-up for new-onset hypertension, as an incidental finding during an imaging study performed for an unrelated reason (pregnancy, trauma, spinal pain, etc), and during evaluation of ADPKD-specific symptoms (hematuria, cyst rupture, pyelonephritis, kidney stones, etc). </p><p>Most patients with ADPKD die from cardiac causes [<a href="#rid65">65</a>]. In one report of 129 patients with ADPKD, causes of death included heart disease (36 percent), infection (24 percent), and a neurologic event (12 percent) [<a href="#rid66">66,67</a>]. Cardiac hypertrophy was seen in 89 percent of autopsied patients and coronary disease in 81 percent. Neurologic deaths were primarily due to ruptured intracranial aneurysm (6 percent) and hypertensive intracerebral hemorrhage (5 percent). No patient died of kidney cancer.</p><p class="headingAnchor" id="H935332681"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H4126093042"><span class="h2">When to suspect ADPKD</span><span class="headingEndMark"> — </span>The diagnosis of ADPKD should be suspected in patients with clinical features mentioned above and in those with a family history of ADPKD. (See <a class="local">'Clinical presentation'</a> above.)</p><p>ADPKD is also sometimes discovered when large kidneys with extensive cysts are observed as an incidental finding in patients who undergo abdominal imaging for a different indication  (<a class="graphic graphic_diagnosticimage graphicRef76800" href="/z/d/graphic/76800.html" rel="external">image 1</a>).</p><p class="headingAnchor" id="H1701894146"><span class="h2">Establishing the diagnosis of ADPKD</span><span class="headingEndMark"> — </span>The initial step toward diagnosis of ADPKD is to obtain a detailed family history from the patient. The diagnosis of ADPKD is confirmed primarily by imaging [<a href="#rid9">9</a>]. Genetic testing is generally reserved for atypical cases or to rule out ADPKD in a young potential kidney donor. However, prior to performing any imaging or genetic testing, patients should be counseled regarding risks and benefits of having an established diagnosis of ADPKD, especially if they are asymptomatic. (See <a class="local">'Diagnostic counseling and screening of family members'</a> below.)</p><p class="headingAnchor" id="H1491145858"><span class="h3">Patients with a family history of ADPKD</span><span class="headingEndMark"> — </span>Criteria for establishing the diagnosis of ADPKD (or excluding the diagnosis) in patients who have a positive family history depends upon the genetic type of ADPKD in their family, if known. Data important to elicit on family history include number and relationship of family members affected, their age at diagnosis, their age of developing end-stage kidney disease (ESKD; if applicable), and any known genetic mutations in the family. In addition to family history, we obtain an initial ultrasound, computed tomography (CT), or magnetic resonance image (MRI) for diagnosis.</p><p>The choice of imaging study for the initial evaluation depends upon family history and presenting features (including kidney function):</p><p class="bulletIndent1"><span class="glyph">●</span>In asymptomatic patients with normal kidney function who have a family history of ADPKD, an ultrasound is usually sufficient to diagnose or rule-out the presence of disease. In these individuals, MRI may be necessary if the results of the ultrasound are equivocal or to further evaluate incidentally detected complications (eg, kidney mass or complex cysts). Some experts perform genetic testing to confirm the diagnosis, if available, as an alternative to follow-up imaging with an MRI. (See <a class="local">'Specific role of genetic testing'</a> below.)</p><p></p><p class="bulletIndent1">If the ultrasound confirms the diagnosis of ADPKD, a baseline CT or MRI, to calculate height-adjusted total kidney volume (htTKV), may be appropriate to evaluate risk for progression and need for disease-modifying treatment (eg, <a class="drug drug_general" data-topicid="9512" href="/z/d/drug information/9512.html" rel="external">tolvaptan</a>). (See  <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Treatment", section on 'Identification of high-risk patients'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with typical findings of ADPKD, such as those with palpable kidneys and decreased estimated glomerular filtration rate (eGFR), and patients with decreased eGFR who have a family history of ADPKD, we obtain a CT or MRI rather than an initial ultrasound. In addition to confirming the diagnosis, a CT or MRI can serve as a baseline image for future comparison, can help identify complications of ADPKD or disease in other organs (eg, pancreas), and can be used to calculate the htTKV for prognostication and planning of treatment. (See  <a class="medical medical_review" href="/z/d/html/1677.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Treatment", section on 'Identification of high-risk patients'</a> and  <a class="medical medical_review" href="/z/d/html/1680.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Kidney manifestations"</a>.)</p><p></p><p class="bulletIndent1">The choice between a CT or MRI depends upon the patient's kidney function, given the risk of contrast exposure with CT. In patients with an eGFR ≥60 mL/min/1.73 m<sup>2</sup>, we obtain a CT without and with contrast. While an unenhanced CT allows calculation of TKV, contrast-enhancement permits differentiation between cystic and noncystic tissue, assessment of cyst burden, and identification of any stones in the collecting system. For patients with an eGFR &lt;60 mL/min/1.73 m<sup>2</sup>, we prefer MRI. MRI is also able to distinguish between cystic and noncystic tissue but is unable to reliably detect kidney stones or parenchymal calcifications. </p><p></p><p>Our imaging preference is based upon available literature and personal experience. Ultrasonography is inexpensive and safe, making it the most commonly used imaging modality for diagnosis. </p><p>Ultrasound-based criteria have been established for diagnosis or exclusion of ADPKD in patients with a positive family history  (<a class="graphic graphic_table graphicRef121625" href="/z/d/graphic/121625.html" rel="external">table 1</a>). These criteria were derived from multiple studies in various populations using ultrasound and molecular genotyping [<a href="#rid68">68-70</a>]. These studies utilized an ultrasound machine capable of detecting cysts that were 1 cm or more in diameter. However, most contemporary ultrasound machines detect kidney cysts of 5 mm or more with certainty. Thus, there has been an overall increase in the sensitivity of cyst detection (from approximately 82 to 97 percent in one study), although it remains center- and operator-dependent [<a href="#rid71">71</a>]. Nevertheless, we continue to use these criteria for diagnosis in individuals with a family history of ADPKD. We use these same criteria for patients who obtain a CT or MRI as the initial diagnostic modality.</p><p>For patients with equivocal ultrasound results, we perform MRI because of its superior sensitivity. Generally, this is required in patients younger than 40 years of age. This is based upon a study of 73 affected (positive genetic testing) and 83 nonaffected (negative genetic testing) individuals, which found that fewer than five cysts by MRI is sufficient to exclude the diagnosis of ADPKD in potential living-related kidney donors [<a href="#rid71">71</a>]. However, they are more expensive, and diagnostic criteria using MRI are based upon only a small number of patients [<a href="#rid71">71</a>].</p><p>In patients with equivocal ultrasound and MRI findings, and a need to establish an accurate diagnosis (eg, for transplant candidacy or prenatal planning), we perform genetic testing (see <a class="local">'Specific role of genetic testing'</a> below). Alternatively, an asymptomatic patient may be followed clinically by monitoring blood pressure and kidney function.</p><p class="headingAnchor" id="H1391458519"><span class="h3">Patient without a family history of ADPKD</span><span class="headingEndMark"> — </span>There are no established imaging-based criteria for diagnosis of ADPKD in patients without a family history. We diagnose these individuals with ADPKD if they have 10 or more cysts (≥5 mm) in each kidney, particularly if the kidneys are enlarged or liver cysts are noted, and obvious features of a different cystic disorder are absent. Genetic testing should be performed, if possible, in patients with equivocal imaging results, or if there is a need to establish an accurate diagnosis (eg, for transplant candidacy or prenatal planning). (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In up to 25 percent of individuals with ADPKD, the clinical presentation and imaging studies suggest a diagnosis of ADPKD, but no one else in the family is known to have the disease [<a href="#rid2">2</a>]. In most such cases, the disease is inherited, but the affected parent has died without a diagnosis or is alive with a mild form of the disease that has gone undetected. Thus, review of medical information or imaging studies of parents or other family members may prove helpful in such patients. In approximately 5 percent of cases, the disease may be due to a new mutation or due to mosaicism [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H3503836549"><span class="h3">Families with rare genotypes</span><span class="headingEndMark"> — </span>Based upon the available data regarding risk of progression, we perform genetic testing for diagnosis among individuals who are from families carrying the <em>DNAJB11</em> mutations [<a href="#rid37">37</a>]. For patients with <em>GANAB</em> or <em>ALG9 </em>mutations, excluding the diagnosis by imaging may be sufficient based upon their mild phenotype [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1152727306"><span class="h3">Specific role of genetic testing</span><span class="headingEndMark"> — </span>We perform genetic testing in the following scenarios: </p><p class="bulletIndent1"><span class="glyph">●</span>Imaging results uncertain, and need for a definitive diagnosis (eg, for a transplant donor).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical presentations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early and severe ADPKD</p><p class="bulletIndent2"><span class="glyph">•</span>Kidney failure without significant enlargement of the kidneys</p><p class="bulletIndent2"><span class="glyph">•</span>Marked discordant disease within family</p><p class="bulletIndent2"><span class="glyph">•</span>Marked asymmetry in disease severity between kidneys</p><p></p><p class="bulletIndent1">Genetic testing in these cases can provide information that explains the atypical presentation, most commonly due to genetic complexity (eg, mutation of a cystic disease gene other than <em>PKD1</em>, <em>PKD2</em> mosaicism, coinheritance of a second mutation in another cystic disease gene, modifier genes). This information may be important among those with atypical presentation who need diagnostic confirmation or information for genetic counseling. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sporadic ADPKD with no family history. (See <a class="local">'Patient without a family history of ADPKD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PKD with syndromic features. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When required for reproductive counseling. (See <a class="local">'Diagnostic counseling and screening of family members'</a> below.)</p><p></p><p>We perform genetic testing by Sanger sequencing of the <em>PKD1</em> and <em>PKD2</em> genes followed by multiplex-dependent probe amplification in cases with negative sequencing results [<a href="#rid73">73</a>]. Next-generation sequencing technologies have a potential for high-throughput screening and lower cost. However, genetic testing remains cost prohibitive for most patients, with significant out-of-pocket costs (up to USD $3000). This cost is expected to decline over time.</p><p>Up to 8 percent of patients with suspected ADPKD do not have mutations in these genes despite a comprehensive screen [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/1682.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Genetics of the disease and mechanisms of cyst growth"</a>.)</p><p class="headingAnchor" id="H2238963328"><span class="h2">Diagnostic counseling and screening of family members</span><span class="headingEndMark"> — </span>Diagnostic counseling by experienced staff is essential for all patients with suspected ADPKD prior to diagnostic testing. </p><p>The benefits derived from testing include knowledge concerning the diagnosis, appropriate family planning, the ability to detect and treat complications associated with the disease, reassurance of unaffected individuals, and appropriate selection of unaffected relatives as possible donors for kidney transplantation. </p><p>Adverse consequences of testing include possible difficulties with employment and insurability (eg, due to creation of a "preexisting condition") and the psychologic impact of having a life-altering diagnosis.</p><p>Additional genetic counseling related to family planning should include discussing the risk of passing the disease to the offspring, reproductive options including preimplantation genetic testing, and risks associated with pregnancy. Some clinicians may choose to refer patients to a genetic counselor. Either way, all of these benefits and risks must be discussed prior to any diagnostic testing.</p><p class="headingAnchor" id="H3877714806"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Disorders other than ADPKD must be considered in the patient with kidney cysts who does not have a family history of the disease. The age of the patient, a family history of other genetic disorders, and the presence of associated manifestations help in the differential diagnosis. </p><p>Acquired disorders that should be considered in adults in the absence of a family history of ADPKD include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple benign simple cysts</strong> – Multiple benign simple cysts are relatively common in the general adult population and increase in number with age. Since they may be difficult to differentiate from a mild form of ADPKD, knowledge concerning the relative prevalence of simple cysts in the general population can help distinguish ADPKD from benign simple cysts. (See  <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults", section on 'Simple kidney cysts'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized kidney cystic disease</strong> – Localized cystic disease of the kidney is an uncommon, benign condition that can be confused with ADPKD [<a href="#rid75">75-77</a>]. In one series of 18 patients, the age at diagnosis ranged from 24 to 83 years (average, 54 years), and none had a family history of ADPKD [<a href="#rid77">77</a>]. Imaging studies revealed multiple cysts of various sizes separated by normal or atrophic parenchyma involving one kidney. In contrast to ADPKD, localized cystic disease is neither bilateral nor progressive [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired kidney cystic disease</strong> – Chronic kidney disease (particularly patients on maintenance hemodialysis or peritoneal dialysis) is frequently associated with the development of multiple and bilateral small cysts; these cysts are usually &lt;0.5 cm in diameter but can be as large as several cm [<a href="#rid78">78</a>]. The diagnosis of acquired cystic disease in kidney disease is established by ultrasonography or CT, although each procedure can have false-negative results. A positive test requires involvement of both kidneys, with four or more cysts being present.</p><p></p><p class="bulletIndent1">Acquired cystic disease is usually easily distinguished from ADPKD since there is no family history of ADPKD and the kidneys are small to normal in size with a smooth contour, as opposed to usually extreme renal enlargement with a cystic contour in ADPKD [<a href="#rid78">78</a>]. Rarely, however, the kidneys in those with acquired kidney cystic disease may enlarge and resemble those of ADPKD. In such cases, acquired kidney cystic disease can be distinguished by the absence of the extrarenal features of ADPKD. (See  <a class="medical medical_review" href="/z/d/html/1683.html" rel="external">"Acquired cystic disease of the kidney in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1679.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD): Extrarenal manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medullary sponge kidney</strong> – Medullary sponge kidney is characterized by tubular dilatation of the collecting ducts confined to the medullary pyramids. The urographic appearance of the kidneys in this disorder can mimic those in ADPKD, although the kidney cortex is spared on CT or MRI. Autosomal dominant inheritance has been reported in some cases [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/7369.html" rel="external">"Medullary sponge kidney"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral parapelvic cysts</strong> – Bilateral parapelvic cysts (eg, cystic disease of the renal sinus) may distort the renal pelvis, infundibula, and calyces and can be confused with ADPKD on excretory urography [<a href="#rid80">80</a>]. The lack of cysts in the cortex distinguishes this disorder from ADPKD.</p><p></p><p>Genetic disorders that should be considered in adults in the absence of a family history of ADPKD include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive polycystic kidney disease (ARPKD)</strong> – In older children or young adults, ARPKD is associated with collecting duct ectasia or macrocystic changes, frequently with nephrolithiasis, hypertension, or impairment of kidney function. Patients also often present with symptoms and signs of hepatic fibrosis and portal hypertension or ascending cholangitis, while neonates may present with enlarged echogenic kidneys and pulmonary hypoplasia. (See  <a class="medical medical_review" href="/z/d/html/6138.html" rel="external">"Autosomal recessive polycystic kidney disease in children"</a>.)</p><p></p><p class="bulletIndent1">The ultrasonographic appearance of the kidney may not distinguish ARPKD from autosomal dominant disease. Extrarenal (hepatic, pancreatic) cysts also favor the presence of autosomal dominant disease, while portal fibrosis or signs of portal hypertension, cholangitis, or biliary dysgenesis favor the diagnosis of autosomal recessive disease.</p><p></p><p class="bulletIndent1">A careful family history and analysis of the parents is often helpful. Ultrasonography of parents of children with ARPKD will not show cysts, while autosomal dominant disease is often first discovered in a parent at the time of diagnosis in the child. However, affected parents with ADPKD under the age of 25 to 30 years may not yet have cysts detectable on ultrasonography, and establishing the diagnosis may require evaluation of the grandparents. Genetic testing may also be helpful in some cases [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant tuberous sclerosis complex</strong> – Patients with tuberous sclerosis can also present with multiple kidney cysts. The diagnosis of tuberous sclerosis is usually confirmed by noting the presence of other features of the disease, such as renal angiomyolipomas, facial angiofibromas, hypomelanotic macules, and retinal nodular hamartomas. (See  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>von Hippel-Lindau disease</strong> – In addition to kidney cysts, patients with von Hippel-Lindau disease may have retinal hemangiomas, clear cell carcinomas of the kidney, cerebellar and spinal hemangioblastomas, pheochromocytoma, endocrine pancreatic tumors, and/or epididymal cystadenoma.</p><p></p><p class="bulletIndent1">Infrequently, patients with kidney cysts, but without the other manifestations of the disorder, may be misdiagnosed with ADPKD. The correct diagnosis is eventually uncovered with the development of a manifestation that is unique to von Hippel-Lindau disease, such as a hemangioblastoma. (See  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant tubulointerstitial kidney disease</strong> – Unlike those with ADPKD, patients with autosomal dominant tubulointerstitial kidney disease may have kidney cysts at the corticomedullary junction, small-to-normal-size kidneys, hyperuricemia, and gout. (See  <a class="medical medical_review" href="/z/d/html/1685.html" rel="external">"Autosomal dominant tubulointerstitial kidney disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant hepatocyte nuclear factor-1beta (HNF-1B) nephropathy</strong> – Autosomal dominant HNF1B-associated nephropathy is characterized by high phenotypic heterogeneity, including: renal structural characteristics (kidney cysts in 60 to 80 percent of patients, multicystic dysplasia, unilateral or bilateral agenesis); tubular transport abnormalities (hypomagnesemia, hypokalemia, hyperuricemia); chronic tubulointerstitial nephropathy; genital tract abnormalities; maturity-onset diabetes of the young; exocrine pancreatic failure; and fluctuating liver test abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal dominant polycystic liver disease (ADPLD)</strong> – ADPLD is distinct from ADPKD because such patients have little or no kidney cyst burden [<a href="#rid82">82</a>]. Nevertheless, in some cases, it is difficult to differentiate mild ADPKD with liver cysts from mild ADPLD with kidney cysts. Although family history may be helpful, genetic testing may be required to make a definitive diagnosis. (See  <a class="medical medical_review" href="/z/d/html/3588.html" rel="external">"Diagnosis and management of cystic lesions of the liver"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked dominant orofaciodigital syndrome type I (OFD1)</strong> – Affected females with X-linked dominant OFD1 (prenatal lethality in males) may have kidneys that are indistinguishable from autosomal dominant polycystic kidneys. Distinguishing features are extrarenal manifestations that include oral (hyperplastic frenula, cleft tongue, cleft palate or lip, and malposed teeth), facial (broad nasal root with hypoplasia of nasal alae and malar bone), and digital (brachy, syn, clino, campto, polydactyly) anomalies [<a href="#rid83">83</a>].</p><p></p><p class="headingAnchor" id="H1738744636"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H29267701"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16253.html" rel="external">"Patient education: Polycystic kidney disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4419.html" rel="external">"Patient education: Polycystic kidney disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder, occurring in approximately 1 in 1000 live births. Approximately 78 percent of families with ADPKD have an abnormality on chromosome 16 (<em>PKD1</em> locus). Most of the remaining families (14 percent) have a different defect that involves a gene on chromosome 4 (the <em>PKD2</em> locus), while a minority of families have a defect in the <em>GANAB </em>gene, encoding the glucosidase II alpha subunit, or the <em>DNAJB11 </em>gene. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for progression</strong> – Patients with <em>PKD2</em> have a less severe phenotype than those with <em>PKD1</em>, but neither disorder is benign. Risk factors for progressive kidney disease in ADPKD include the causative gene mutation within the context of family history, male sex, onset of symptoms at an early age, kidney size, presence of hypertension, proteinuria, and high urinary sodium excretion. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Patients with ADPKD may be asymptomatic or present with hypertension, hematuria, proteinuria, or kidney function impairment, detected by routine laboratory examination. Flank pain due to kidney hemorrhage, calculi, or urinary tract infection are the most common symptoms reported by patients. Patients may also present with symptoms that are secondary to cysts in other organs, such as the liver, pancreas, spleen, or epididymis. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to suspect ADPKD</strong> – The diagnosis is most commonly made in the settings of routine evaluation in an asymptomatic patient with a positive family history of ADPKD, initial work-up for new-onset hypertension, as an incidental finding during an imaging study performed for an unrelated reason (eg, pregnancy, trauma, spinal pain), and during evaluation of ADPKD-specific symptoms (hematuria, cyst rupture, pyelonephritis, kidney stones, etc). (See <a class="local">'When to suspect ADPKD'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic counseling</strong> – Diagnostic counseling by experienced staff is essential for all patients with suspected ADPKD prior to diagnostic testing. The benefits and adverse consequences of diagnostic testing, as well as genetic counseling related to family planning, when relevant, should be discussed. (See <a class="local">'Diagnostic counseling and screening of family members'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Establishing the diagnosis</strong> – Diagnostic confirmation of ADPKD is primarily by imaging. Genetic testing is generally reserved for atypical cases or to rule out ADPKD in a young potential kidney donor (see <a class="local">'Specific role of genetic testing'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among patients with a family history of ADPKD, who are asymptomatic with normal kidney function, an ultrasound is usually sufficient to diagnose or rule-out the presence of disease  (<a class="graphic graphic_table graphicRef121625" href="/z/d/graphic/121625.html" rel="external">table 1</a>). In these individuals, magnetic resonance imaging (MRI) may be necessary if the results of the ultrasound are equivocal or to further evaluate incidentally detected complications (eg, kidney mass or complex cysts). Some experts perform genetic testing to confirm the diagnosis, if available, as an alternative to follow-up imaging with an MRI. (See <a class="local">'Patients with a family history of ADPKD'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among patients with a family history and typical findings of ADPKD, such as those with palpable kidneys and decreased estimated glomerular filtration rate (eGFR), we obtain a computed tomography (CT) or MRI rather than an initial ultrasound. The choice between a CT or MRI depends upon the patient's kidney function, given the risk of contrast exposure with CT. In patients with an eGFR ≥60 mL/min/1.73 m<sup>2</sup>, we obtain a CT without and with contrast. For patients with an eGFR &lt;60 mL/min/1.73 m<sup>2</sup>, we prefer MRI. (See <a class="local">'Patients with a family history of ADPKD'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There are no established imaging-based criteria for diagnosis of ADPKD in patients without a family history. We diagnose these individuals with ADPKD if they have 10 or more cysts (≥5 mm) in each kidney, particularly if the kidneys are enlarged or liver cysts are noted, and obvious features of a different cystic disorder are absent. Genetic testing should be performed, if possible, in patients with equivocal imaging results or if there is a need to establish an accurate diagnosis (eg, for transplant candidacy or prenatal planning). (See <a class="local">'Patient without a family history of ADPKD'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Based on the available data regarding risk of progression, we perform genetic testing for diagnosis among individuals who are from families carrying the <em>DNAJB11</em> mutations. For patients with <em>GANAB</em> mutations, excluding the diagnosis by imaging may be sufficient based on their mild phenotype.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differential diagnosis</strong> – Disorders other than ADPKD must be considered in the patient with kidney cysts who does not have a family history of the disease. The age of the patient, a family history of other genetic disorders, and the presence of associated manifestations help differentiate between various conditions. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Davies F, Coles GA, Harper PS, et al. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991; 79:477.</a></li><li><a class="nounderline abstract_t">Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.</a></li><li><a class="nounderline abstract_t">Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.</a></li><li class="breakAll">Harris PC, Torres VE. Autosomal dominant polycystic kidney disease. Gene Clinics Online Reviews at Gene Tests-Gene Clinics (University of Washington, Seattle, 2002).</li><li><a class="nounderline abstract_t">Besse W, Chang AR, Luo JZ, et al. ALG9 Mutation Carriers Develop Kidney and Liver Cysts. J Am Soc Nephrol 2019; 30:2091.</a></li><li><a class="nounderline abstract_t">Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.</a></li><li><a class="nounderline abstract_t">Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353:103.</a></li><li><a class="nounderline abstract_t">Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76:149.</a></li><li><a class="nounderline abstract_t">Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.</a></li><li><a class="nounderline abstract_t">Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009; 60:321.</a></li><li><a class="nounderline abstract_t">Peters DJ, Breuning MH. Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 2001; 358:1439.</a></li><li><a class="nounderline abstract_t">Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 41:1311.</a></li><li><a class="nounderline abstract_t">Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997; 8:1560.</a></li><li><a class="nounderline abstract_t">Fick-Brosnahan GM, Tran ZV, Johnson AM, et al. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 2001; 59:1654.</a></li><li><a class="nounderline abstract_t">Fick-Brosnahan GM, Belz MM, McFann KK, et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39:1127.</a></li><li><a class="nounderline abstract_t">King BF, Torres VE, Brummer ME, et al. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64:2214.</a></li><li><a class="nounderline abstract_t">Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42:1305.</a></li><li><a class="nounderline abstract_t">Yium J, Gabow P, Johnson A, et al. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 1994; 4:1670.</a></li><li><a class="nounderline abstract_t">Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63:678.</a></li><li><a class="nounderline abstract_t">Torres VE, Grantham JJ, Chapman AB, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6:640.</a></li><li><a class="nounderline abstract_t">Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012; 27:4131.</a></li><li><a class="nounderline abstract_t">Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM 2013; 106:639.</a></li><li><a class="nounderline abstract_t">Schrier RW, Brosnahan G, Cadnapaphornchai MA, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 2014; 25:2399.</a></li><li><a class="nounderline abstract_t">Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet 1994; 8:328.</a></li><li><a class="nounderline abstract_t">Rossetti S, Burton S, Strmecki L, et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002; 13:1230.</a></li><li><a class="nounderline abstract_t">Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2007; 18:1374.</a></li><li><a class="nounderline abstract_t">Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009; 20:1833.</a></li><li><a class="nounderline abstract_t">Connor A, Lunt PW, Dolling C, et al. Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation. Am J Transplant 2008; 8:232.</a></li><li><a class="nounderline abstract_t">Consugar MB, Wong WC, Lundquist PA, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int 2008; 74:1468.</a></li><li><a class="nounderline abstract_t">Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009; 75:848.</a></li><li><a class="nounderline abstract_t">Fain PR, McFann KK, Taylor MR, et al. Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 2005; 67:1256.</a></li><li><a class="nounderline abstract_t">Persu A, Duyme M, Pirson Y, et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 2004; 66:2132.</a></li><li><a class="nounderline abstract_t">Baboolal K, Ravine D, Daniels J, et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52:607.</a></li><li><a class="nounderline abstract_t">O'Sullivan DA, Torres VE, Gabow PA, et al. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32:976.</a></li><li><a class="nounderline abstract_t">Persu A, Devuyst O, Lannoy N, et al. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11:2285.</a></li><li><a class="nounderline abstract_t">Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet 2016; 98:1193.</a></li><li><a class="nounderline abstract_t">Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet 2018; 102:832.</a></li><li><a class="nounderline abstract_t">Huynh VT, Audrézet MP, Sayer JA, et al. Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. Kidney Int 2020; 98:476.</a></li><li><a class="nounderline abstract_t">Cornec-Le Gall E, Torres VE, Harris PC. Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 2018; 29:13.</a></li><li><a class="nounderline abstract_t">Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest 2017; 127:3558.</a></li><li><a class="nounderline abstract_t">Chebib FT, Torres VE. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 2018; 13:1765.</a></li><li><a class="nounderline abstract_t">Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015; 26:160.</a></li><li><a class="nounderline abstract_t">Girardat-Rotar L, Braun J, Puhan MA, et al. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients. BMC Nephrol 2017; 18:241.</a></li><li><a class="nounderline abstract_t">Irazabal MV, Blais JD, Perrone RD, et al. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial. Kidney Int Rep 2016; 1:213.</a></li><li><a class="nounderline abstract_t">Irazabal MV, Abebe KZ, Bae KT, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 2017; 32:1857.</a></li><li><a class="nounderline abstract_t">Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38:1177.</a></li><li><a class="nounderline abstract_t">Taylor M, Johnson AM, Tison M, et al. Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis 2005; 46:415.</a></li><li><a class="nounderline abstract_t">Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S. Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int 2012; 81:919.</a></li><li><a class="nounderline abstract_t">Dicks E, Ravani P, Langman D, et al. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 2006; 1:710.</a></li><li><a class="nounderline abstract_t">Pei Y. Nature and nurture on phenotypic variability of autosomal dominant polycystic kidney disease. Kidney Int 2005; 67:1630.</a></li><li><a class="nounderline abstract_t">Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1349.</a></li><li><a class="nounderline abstract_t">Sharp C, Johnson A, Gabow P. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1998; 9:1908.</a></li><li><a class="nounderline abstract_t">Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1:148.</a></li><li><a class="nounderline abstract_t">Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384.</a></li><li><a class="nounderline abstract_t">Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006; 17:3013.</a></li><li><a class="nounderline abstract_t">Bergmann C, Brüchle NO, Frank V, et al. Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation. N Engl J Med 2008; 359:318.</a></li><li><a class="nounderline abstract_t">Iguchi S, Kasai A, Kishimoto H, et al. Thrombosis in inferior vena cava (IVC) due to intra-cystic hemorrhage into a hepatic local cyst with autosomal dominant polycystic kidney disease (ADPKD). Intern Med 2004; 43:209.</a></li><li><a class="nounderline abstract_t">Tamburrini R, Ahmed Z, van der Walt J, Goldsmith D. Sudden death of a patient with polycystic kidneys due to acute inferior vena cava thrombosis. Scott Med J 2016; 61:171.</a></li><li><a class="nounderline abstract_t">Maeda T, Uchida Y, Oyamada K, Nakajima F. Thrombosis in inferior vena cava due to enlarged renal cysts in autosomal dominant polycystic kidney disease. Intern Med 2010; 49:1891.</a></li><li><a class="nounderline abstract_t">England RA, Wells IP, Gutteridge CM. Benign external compression of the inferior vena cava associated with thrombus formation. Br J Radiol 2005; 78:553.</a></li><li><a class="nounderline abstract_t">O'Sullivan DA, Torres VE, Heit JA, et al. Compression of the inferior vena cava by right renal cysts: an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease. Clin Nephrol 1998; 49:332.</a></li><li><a class="nounderline abstract_t">Pierre SA, Jaeger MT, Siemens DR. Intra-operative inferior vena cava syndrome in a patient with autosomal dominant polycystic kidney disease. World J Urol 2006; 24:110.</a></li><li><a class="nounderline abstract_t">Holzmann-Littig C, Lorenz G, Wen M, et al. A case of pulmonary embolism caused by compression of the vena cava by intra-abdominal masses in autosomal polycystic kidney disease. Clin Case Rep 2020; 8:1149.</a></li><li><a class="nounderline abstract_t">Xiaorui Yin, Jon D. Blumenfeld, Sadjad Riyahi, Hanna Rennert. Prevalence of Inferior Vena Cava Compression in ADPKD. Kidney International Reports 2021; 6:168.</a></li><li><a class="nounderline abstract_t">Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38:777.</a></li><li><a class="nounderline abstract_t">Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5:2048.</a></li><li><a class="nounderline abstract_t">Spithoven EM, Kramer A, Meijer E, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 2014; 29 Suppl 4:iv15.</a></li><li><a class="nounderline abstract_t">Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20:205.</a></li><li><a class="nounderline abstract_t">Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343:824.</a></li><li><a class="nounderline abstract_t">Nicolau C, Torra R, Badenas C, et al. Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US sensitivity for diagnosis. Radiology 1999; 213:273.</a></li><li><a class="nounderline abstract_t">Pei Y, Hwang YH, Conklin J, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2015; 26:746.</a></li><li><a class="nounderline abstract_t">Tan AY, Blumenfeld J, Michaeel A, et al. Autosomal dominant polycystic kidney disease caused by somatic and germline mosaicism. Clin Genet 2015; 87:373.</a></li><li><a class="nounderline abstract_t">Chebib FT, Torres VE. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016. Am J Kidney Dis 2016; 67:792.</a></li><li><a class="nounderline abstract_t">Heyer CM, Sundsbak JL, Abebe KZ, et al. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2016; 27:2872.</a></li><li><a class="nounderline abstract_t">Bisceglia M, Cretì G. AMR series unilateral (localized) renal cystic disease. Adv Anat Pathol 2005; 12:227.</a></li><li><a class="nounderline abstract_t">Fick-Brosnahan G, Johnson AM, Strain JD, Gabow PA. Renal asymmetry in children with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34:639.</a></li><li><a class="nounderline abstract_t">Slywotzky CM, Bosniak MA. Localized cystic disease of the kidney. AJR Am J Roentgenol 2001; 176:843.</a></li><li><a class="nounderline abstract_t">Levine E. Acquired cystic kidney disease. Radiol Clin North Am 1996; 34:947.</a></li><li><a class="nounderline abstract_t">Gambaro G, Feltrin GP, Lupo A, et al. Medullary sponge kidney (Lenarduzzi-Cacchi-Ricci disease): a Padua Medical School discovery in the 1930s. Kidney Int 2006; 69:663.</a></li><li><a class="nounderline abstract_t">Murray KK, McLellan GL. Renal peripelvic lymphangiectasia: appearance at CT. Radiology 1991; 180:455.</a></li><li><a class="nounderline abstract_t">Zerres K, Senderek J, Rudnik-Schöneborn S, et al. New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene. Clin Genet 2004; 66:53.</a></li><li><a class="nounderline abstract_t">Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest 2017; 127:1772.</a></li><li><a class="nounderline abstract_t">Thauvin-Robinet C, Cossée M, Cormier-Daire V, et al. Clinical, molecular, and genotype-phenotype correlation studies from 25 cases of oral-facial-digital syndrome type 1: a French and Belgian collaborative study. J Med Genet 2006; 43:54.</a></li></ol></div><div id="topicVersionRevision">Topic 1678 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1946928" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Polycystic kidney disease re-evaluated: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8321262" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972657" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Estimating prevalence in single-gene kidney diseases progressing to renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972657" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Estimating prevalence in single-gene kidney diseases progressing to renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395617" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ALG9 Mutation Carriers Develop Kidney and Liver Cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832246" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical practice. Autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023895" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19455193" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Autosomal dominant polycystic kidney disease: the last 3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18947299" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705510" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Autosomal dominant polycystic kidney disease: modification of disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614046" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9335384" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11318935" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Progression of autosomal-dominant polycystic kidney disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12046022" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633145" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655206" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cystic and inherited kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011976" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631134" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088290" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523115" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587574" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24925719" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Predictors of autosomal dominant polycystic kidney disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7894481" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961010" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429049" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443633" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Family history of renal disease severity predicts the mutated gene in ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17973957" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mosaicism in autosomal dominant polycystic kidney disease revealed by genetic testing to enable living related renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818683" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165178" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780078" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Modifier genes play a significant role in the phenotypic expression of PKD1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569302" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison between siblings and twins supports a role for modifier genes in ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291178" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856513" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095651" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27259053" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mutations in GANAB, Encoding the Glucosidase IIαSubunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706351" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32631624" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29038287" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28862642" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Isolated polycystic liver disease genes define effectors of polycystin-1 function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30049849" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24904092" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716055" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142926" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27484667" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2074659" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Renal structure and hypertension in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129202" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22297678" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699277" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780121" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nature and nurture on phenotypic variability of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7894001" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773792" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699202" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191984" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Genetics and pathogenesis of polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035604" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635443" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15098602" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Thrombosis in inferior vena cava (IVC) due to intra-cystic hemorrhage into a hepatic local cyst with autosomal dominant polycystic kidney disease (ADPKD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25634914" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sudden death of a patient with polycystic kidneys due to acute inferior vena cava thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823652" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Thrombosis in inferior vena cava due to enlarged renal cysts in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900063" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Benign external compression of the inferior vena cava associated with thrombus formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9617502" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Compression of the inferior vena cava by right renal cysts: an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16435147" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intra-operative inferior vena cava syndrome in a patient with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32695346" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A case of pulmonary embolism caused by compression of the vena cava by intra-abdominal masses in autosomal polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence of Inferior Vena Cava Compression in ADPKD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576881" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579053" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Causes of death in autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25165182" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945943" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Unified criteria for ultrasonographic diagnosis of ADPKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7908078" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10540671" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US sensitivity for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25074509" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Imaging-based diagnosis of autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24641620" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Autosomal dominant polycystic kidney disease caused by somatic and germline mosaicism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26530876" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26823553" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16096385" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : AMR series unilateral (localized) renal cystic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516343" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Renal asymmetry in children with autosomal dominant polycystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11264061" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Localized cystic disease of the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784391" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acquired cystic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395272" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Medullary sponge kidney (Lenarduzzi-Cacchi-Ricci disease): a Padua Medical School discovery in the 1930s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2068311" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Renal peripelvic lymphangiectasia: appearance at CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200508" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : New options for prenatal diagnosis in autosomal recessive polycystic kidney disease by mutation analysis of the PKHD1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28375157" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Isolated polycystic liver disease genes define effectors of polycystin-1 function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16397067" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clinical, molecular, and genotype-phenotype correlation studies from 25 cases of oral-facial-digital syndrome type 1: a French and Belgian collaborative study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
